Contrast MediaContrast Agents Market Size Will Surpass USD 6389.31 Million By 2030 at 3.4 percent CAGR Growth - Benzinga
| ACBM Stock | USD 0 0.00 0.00% |
About 56% of ACRO Biomedical's investor base is looking to short. The analysis of overall sentiment of trading ACRO Biomedical Co pink sheet suggests that many investors are alarmed at this time. ACRO Biomedical's investing sentiment overview a quick insight into current market opportunities from investing in ACRO Biomedical Co. Many technical investors use ACRO Biomedical stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
ACRO Biomedical pink sheet news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of ACRO daily returns and investor perception about the current price of ACRO Biomedical Co as well as its diversification or hedging effects on your existing portfolios.
ACRO |
Contrast MediaContrast Agents Market Size Will Surpass USD 6389.31 Million By 2030 at 3.4 percent CAGR Growth Benzinga
Read at news.google.com
 |
ACRO Biomedical Fundamental Analysis
We analyze ACRO Biomedical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ACRO Biomedical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ACRO Biomedical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Book
Price To Book Comparative Analysis
ACRO Biomedical is currently under evaluation in price to book category among its peers. Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
ACRO Biomedical Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with ACRO Biomedical pink sheet to make a market-neutral strategy. Peer analysis of ACRO Biomedical could also be used in its relative valuation, which is a method of valuing ACRO Biomedical by comparing valuation metrics with similar companies.
Peers
ACRO Biomedical Related Equities
| ACLX | Arcellx | 8.57 | ||||
| PTIX | Protagenic Therapeutics | 5.77 | ||||
| ACRV | Acrivon Therapeutics, | 4.52 | ||||
| NXTC | NextCure | 4.42 | ||||
| IKNA | Ikena Oncology | 1.80 | ||||
| DSGN | Design Therapeutics | 1.69 | ||||
| XLO | Xilio Development | 0.93 | ||||
| ANEB | Anebulo Pharmaceuticals | 0.64 | ||||
| HOWL | Werewolf Therapeutics | 0.54 | ||||
| NGENF | NervGen Pharma | 0.54 | ||||
| MLYS | Mineralys Therapeutics, | 1.43 | ||||
| AVTE | Aerovate Therapeutics | 2.23 | ||||
| TRVI | Trevi Therapeutics | 2.24 | ||||
| NUVB | Nuvation Bio | 3.21 | ||||
| ACXP | Acurx Pharmaceuticals | 3.23 | ||||
| STOK | Stoke Therapeutics | 3.63 | ||||
| GLUE | Monte Rosa | 7.45 | ||||
| ADAG | Adagene | 13.04 |
Other Information on Investing in ACRO Pink Sheet
ACRO Biomedical financial ratios help investors to determine whether ACRO Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in ACRO with respect to the benefits of owning ACRO Biomedical security.